Data Year:

For its 2025 fiscal year, NEOGENOMICS INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In Healthcare industry
Warren C. Stone
Chief Commercial Officer
Total Compensation $5,068,830 View details Pay Rank By Title In Healthcare industry #8 View more
Christopher M. Smith
Former Director and Former Chief Executive Officer
Total Compensation $4,045,937 View details Pay Rank By Title In Healthcare industry #43 View more
Jeffrey S. Sherman
Chief Financial Officer
Total Compensation $4,681,428 View details Pay Rank By Title In Healthcare industry #17 View more
Tony Zook
Director and Chief Executive Officer
Total Compensation $9,127,092 View details Pay Rank By Title In Healthcare industry #25 View more
Melody Harris
Former Chief Operations Officer and Former President, Oncology Data Solutions
Total Compensation $3,692,445 View details Pay Rank By Title In Healthcare industry #12 View more
Alicia C. Olivo
Executive Vice President, General Counsel and Business Development
Total Compensation $3,049,999 View details Pay Rank By Title In Healthcare industry #12 View more
Gary Passman
Chief Culture Officer
Total Compensation $2,443,195 View details Pay Rank By Title In Healthcare industry #10 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at NEOGENOMICS INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. NEOGENOMICS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. NEOGENOMICS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Warren C. Stone
Chief Commercial Officer
Total Cash $1,305,069 Equity $3,749,761 Other $14,000 $5,068,830
Christopher M. Smith
Former Director and Former Chief Executive Officer
Total Cash $466,716 Equity $3,350,004 Other $229,217 $4,045,937
Jeffrey S. Sherman
Chief Financial Officer
Total Cash $917,731 Equity $3,749,697 Other $14,000 $4,681,428
Tony Zook
Director and Chief Executive Officer
Total Cash $1,114,939 Equity $7,998,232 Other $13,921 $9,127,092
Melody Harris
Former Chief Operations Officer and Former President, Oncology Data Solutions
Total Cash $421,560 Equity $2,579,500 Other $691,385 $3,692,445
Alicia C. Olivo
Executive Vice President, General Counsel and Business Development
Total Cash $793,500 Equity $2,249,845 Other $6,654 $3,049,999
Gary Passman
Chief Culture Officer
Total Cash $686,962 Equity $1,749,871 Other $6,362 $2,443,195
For its 2025 fiscal year, NEOGENOMICS INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Tony Zook CEO Pay $9,375,553 Median Employee Pay $101,144 CEO Pay Ratio 93:1
For its 2024 fiscal year, NEOGENOMICS INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Alison L. Hannah Total Cash $309,382
Anthony P. Zook Total Cash $320,357
Bruce K. Crowther Total Cash $26,703
David B. Perez Total Cash $310,882
Elizabeth A. Floegel Total Cash $305,000
Felicia Williams Total Cash $149,833
Lynn A. Tetrault Total Cash $370,100
Michael A. Kelly Total Cash $318,925
Neil Gunn Total Cash $314,864
Stephen M. Kanovsky Total Cash $312,050
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.